Literature DB >> 33803403

Design, Synthesis, and Evaluation of Novel 3-Carboranyl-1,8-Naphthalimide Derivatives as Potential Anticancer Agents.

Sebastian Rykowski1, Dorota Gurda-Woźna2, Marta Orlicka-Płocka2, Agnieszka Fedoruk-Wyszomirska2, Małgorzata Giel-Pietraszuk2, Eliza Wyszko2, Aleksandra Kowalczyk3, Paweł Stączek3, Andrzej Bak4, Agnieszka Kiliszek2, Wojciech Rypniewski2, Agnieszka B Olejniczak1.   

Abstract

We synthesized a series of novel 3-carboranyl-1,8-naphthalimide derivatives, mitonafide and pinafide analogs, using click chemistry, reductive amination and amidation reactions and investigated their in vitro effects on cytotoxicity, cell death, cell cycle, and the production of reactive oxygen species in a HepG2 cancer cell line. The analyses showed that modified naphthalic anhydrides and naphthalimides bearing ortho- or meta-carboranes exhibited diversified activity. Naphthalimides were more cytotoxic than naphthalic anhydrides, with the highest IC50 value determined for compound 9 (3.10 µM). These compounds were capable of inducing cell cycle arrest at G0/G1 or G2M phase and promoting apoptosis, autophagy or ferroptosis. The most promising conjugate 35 caused strong apoptosis and induced ROS production, which was proven by the increased level of 2'-deoxy-8-oxoguanosine in DNA. The tested conjugates were found to be weak topoisomerase II inhibitors and classical DNA intercalators. Compounds 33, 34, and 36 fluorescently stained lysosomes in HepG2 cells. Additionally, we performed a similarity-based assessment of the property profile of the conjugates using the principal component analysis. The creation of an inhibitory profile and descriptor-based plane allowed forming a structure-activity landscape. Finally, a ligand-based comparative molecular field analysis was carried out to specify the (un)favorable structural modifications (pharmacophoric pattern) that are potentially important for the quantitative structure-activity relationship modeling of the carborane-naphthalimide conjugates.

Entities:  

Keywords:  anticancer activity; carborane; naphthalimides

Mesh:

Substances:

Year:  2021        PMID: 33803403      PMCID: PMC7967199          DOI: 10.3390/ijms22052772

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  70 in total

1.  The binding of ethidium bromide with DNA: interaction with single- and double-stranded structures.

Authors:  P O Vardevanyan; A P Antonyan; M A Parsadanyan; H G Davtyan; A T Karapetyan
Journal:  Exp Mol Med       Date:  2003-12-31       Impact factor: 8.718

2.  Spectrometric and voltammetric investigation of interaction of neutral red with calf thymus DNA: pH effect.

Authors:  Xiue Jiang; Li Shang; Zhenxin Wang; Shaojun Dong
Journal:  Biophys Chem       Date:  2005-10-22       Impact factor: 2.352

Review 3.  Cu-catalyzed azide-alkyne cycloaddition.

Authors:  Morten Meldal; Christian Wenzel Tornøe
Journal:  Chem Rev       Date:  2008-08       Impact factor: 60.622

Review 4.  Systematic computational analysis of structure-activity relationships: concepts, challenges and recent advances.

Authors:  Lisa Peltason; Jürgen Bajorath
Journal:  Future Med Chem       Date:  2009-06       Impact factor: 3.808

Review 5.  Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds.

Authors:  Fatiah Issa; Michael Kassiou; Louis M Rendina
Journal:  Chem Rev       Date:  2011-06-30       Impact factor: 60.622

6.  Synthesis of naphthalimide-carborane and metallacarborane conjugates: Anticancer activity, DNA binding ability.

Authors:  Jan Nekvinda; Daria Różycka; Sebastian Rykowski; Eliza Wyszko; Agnieszka Fedoruk-Wyszomirska; Dorota Gurda; Marta Orlicka-Płocka; Małgorzata Giel-Pietraszuk; Agnieszka Kiliszek; Wojciech Rypniewski; Rafał Bachorz; Jakub Wojcieszak; Bohumir Grüner; Agnieszka B Olejniczak
Journal:  Bioorg Chem       Date:  2019-11-19       Impact factor: 5.275

7.  Different conformations of double-stranded nucleic acid in solution as revealed by circular dichroism.

Authors:  V I Ivanov; L E Minchenkova; A K Schyolkina; A I Poletayev
Journal:  Biopolymers       Date:  1973       Impact factor: 2.505

Review 8.  l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.

Authors:  Mateusz D Tomczyk; Krzysztof Z Walczak
Journal:  Eur J Med Chem       Date:  2018-09-24       Impact factor: 6.514

9.  Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents.

Authors:  H Kasai; S Nishimura
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

10.  Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds.

Authors:  A Pain; S Samanta; S Dutta; A K Saxena; M Shanmugavel; H Kampasi; G N Quazi; U Sanyal
Journal:  Acta Pol Pharm       Date:  2003 Jul-Aug       Impact factor: 0.330

View more
  3 in total

1.  Design of DNA Intercalators Based on 4-Carboranyl-1,8-Naphthalimides: Investigation of Their DNA-Binding Ability and Anticancer Activity.

Authors:  Sebastian Rykowski; Dorota Gurda-Woźna; Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Małgorzata Giel-Pietraszuk; Eliza Wyszko; Aleksandra Kowalczyk; Paweł Stączek; Katarzyna Biniek-Antosiak; Wojciech Rypniewski; Agnieszka B Olejniczak
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

3.  Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives.

Authors:  Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Dorota Gurda-Woźna; Paweł Pawelczak; Patrycja Krawczyk; Małgorzata Giel-Pietraszuk; Grzegorz Framski; Tomasz Ostrowski; Eliza Wyszko
Journal:  Antioxidants (Basel)       Date:  2021-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.